News Headlines Article

Death Sentence No Longer a Given for Patients With Melanoma
San Francisco Chronicle

Nathan Schwegman was just 25 when his doctor told him he had a 3 percent chance of surviving the melanoma that had spread into his lungs and spine, soon leaving him in so much pain he could hardly move. A month later, in January 2012, he enrolled in a clinical trial testing a new drug from Merck & Co. that was designed to rev up his immune system to attack and kill his cancer. In just two months, the pain started going away. Now he’s cancer free.